Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innovent Biologics ( (HK:1801) ) has provided an update.
Innovent Biologics announced that China’s National Medical Products Administration has approved its CTLA-4 monoclonal antibody TABOSUN (ipilimumab N01 injection) in combination with its PD-1 inhibitor sintilimab as a neoadjuvant treatment for stage IIB–III resectable MSI-H or dMMR colon cancer. The product is the first domestically developed CTLA-4 antibody approved in China and the world’s first CTLA-4 therapy cleared for neoadjuvant use in colon cancer, positioning Innovent at the forefront of dual immune-oncology regimens and potentially reshaping pre-surgical treatment standards for this hard-to-treat subset of patients. The approval, backed by strong pathological complete response data from Phase 1b and pivotal Phase 3 studies showing markedly higher pCR rates without significant added safety risks versus surgery alone, underscores the company’s growing clinical and commercial footprint in immuno-oncology and may reduce reliance on adjuvant chemotherapy for patients with resectable MSI-H/dMMR colon cancer.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$115.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development and commercialization of monoclonal antibody drugs and other innovative biologics, targeting major disease areas such as oncology with an emphasis on the Chinese market.
YTD Price Performance: 120.63%
Average Trading Volume: 14,991,261
Technical Sentiment Signal: Buy
Current Market Cap: HK$139B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.